Health Canada has approved Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) by Bausch Health and Glenmark for the symptomatic treatment of moderate-to-severe Seasonal Allergic Rhinitis (SAR) and associated ocular symptoms in adults, adolescents and children aged six years and older, the companies said in a joint statement.
Ryaltris is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes after administration of Ryaltris, said the statement.